Johns Hopkins Will Work With Clearmind On Alcohol Addiction Research Program
Portfolio Pulse from Lara Goldstein
Clearmind Medicine (NASDAQ:CMND) has partnered with Johns Hopkins University School of Medicine to conduct a Phase I/IIa clinical trial on its proprietary MEAI-based compound CMND-100 for the potential treatment of Alcohol Use Disorder. The clinical program will involve a multinational, multi-center study in both healthy volunteers and people with AUD. This is the second US clinical site to join the trial, following Yale School of Medicine’s Department of Psychiatry.
September 06, 2023 | 9:36 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Clearmind's partnership with Johns Hopkins for a clinical trial on its compound CMND-100 could potentially boost its reputation and stock value if the trial proves successful.
The partnership with a reputable institution like Johns Hopkins for a clinical trial on its compound CMND-100 could potentially boost Clearmind's reputation and stock value. The success of the trial could lead to increased investor confidence and demand for the stock, driving up its price.
CONFIDENCE 70
IMPORTANCE 80
RELEVANCE 100